Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6589) 6589
Newsletter (430) 430
Newspaper Article (147) 147
Book Chapter (73) 73
Magazine Article (53) 53
Dissertation (22) 22
Conference Proceeding (5) 5
Web Resource (3) 3
Transcript (2) 2
Book / eBook (1) 1
Publication (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tenofovir (6093) 6093
science & technology (4297) 4297
humans (4202) 4202
life sciences & biomedicine (3946) 3946
adenine - analogs & derivatives (2591) 2591
female (2359) 2359
infectious diseases (2317) 2317
male (2284) 2284
hiv infections - drug therapy (2055) 2055
adult (1969) 1969
hiv (1827) 1827
human immunodeficiency virus--hiv (1508) 1508
middle aged (1481) 1481
adenine - therapeutic use (1433) 1433
antiviral agents (1348) 1348
anti-hiv agents - therapeutic use (1321) 1321
emtricitabine (1251) 1251
hepatitis b (1241) 1241
organophosphonates - therapeutic use (1193) 1193
immunology (1139) 1139
drug therapy (1128) 1128
pharmacology & pharmacy (1075) 1075
virology (1055) 1055
biological and medical sciences (1017) 1017
medical sciences (995) 995
anti-hiv agents - administration & dosage (958) 958
aids/hiv (918) 918
treatment outcome (885) 885
antiretroviral drugs (878) 878
hiv infection (874) 874
adenine - administration & dosage (872) 872
research (806) 806
microbiology (797) 797
viral diseases (794) 794
health aspects (789) 789
lamivudine (773) 773
anti-hiv agents - adverse effects (770) 770
organophosphonates - administration & dosage (763) 763
hiv infections - prevention & control (761) 761
drug therapy, combination (740) 740
adenine - adverse effects (721) 721
deoxycytidine - analogs & derivatives (700) 700
antiviral agents - therapeutic use (693) 693
human viral diseases (679) 679
pharmacology. drug treatments (675) 675
tenofovir - therapeutic use (650) 650
hepatitis b, chronic - drug therapy (648) 648
antiretroviral therapy (645) 645
hepatitis b virus (645) 645
organophosphonates - adverse effects (613) 613
viral load (609) 609
virus diseases (597) 597
hepatitis (590) 590
hiv infections - virology (589) 589
antibiotics. antiinfectious agents. antiparasitic agents (581) 581
care and treatment (581) 581
risk factors (571) 571
gastroenterology & hepatology (555) 555
young adult (554) 554
hiv-1 - drug effects (553) 553
analysis (545) 545
dosage and administration (525) 525
clinical trials (523) 523
highly active antiretroviral therapy (522) 522
viral diseases of the lymphoid tissue and the blood. aids (519) 519
infections (498) 498
patients (496) 496
aids (495) 495
lamivudine - therapeutic use (490) 490
reverse transcriptase inhibitors - therapeutic use (489) 489
prevention (481) 481
entecavir (465) 465
drug combinations (456) 456
acquired immune deficiency syndrome--aids (444) 444
hiv infections - complications (440) 440
medical research (430) 430
drug resistance (429) 429
adolescent (414) 414
adenine - pharmacology (413) 413
animals (407) 407
antiretroviral agents (403) 403
medicine (394) 394
deoxycytidine - therapeutic use (390) 390
tenofovir - administration & dosage (389) 389
human immunodeficiency virus (381) 381
mutation (380) 380
viruses (379) 379
drug resistance, viral (377) 377
aged (375) 375
tenofovir disoproxil fumarate (372) 372
guanine - analogs & derivatives (366) 366
abridged index medicus (365) 365
cd4 lymphocyte count (354) 354
retrospective studies (351) 351
deoxycytidine - administration & dosage (350) 350
hiv-1 (346) 346
organophosphonates (343) 343
anti-hiv agents - pharmacology (331) 331
medicine, experimental (328) 328
organophosphonates - pharmacology (328) 328
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6930) 6930
Korean (140) 140
Spanish (94) 94
French (64) 64
German (61) 61
Portuguese (44) 44
Chinese (27) 27
Japanese (15) 15
Hungarian (14) 14
Turkish (10) 10
Czech (8) 8
Italian (7) 7
Dutch (3) 3
Indonesian (2) 2
Polish (2) 2
Croatian (1) 1
Hebrew (1) 1
Persian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Atteintes rénales chez les personnes vivant avec le VIH traitées en Afrique par une combinaison antirétrovirale comprenant du tenofovir disoproxil fumarate
by Letertre-Gibert, P and Diallo, I and Pereira, B and Coban, D and Heng, A and Lesens, O and Laurichesse, H and Drabo, Y and Jacomet, C
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2017, Volume 47, Issue 4, pp. S137 - S137
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text VIH-15 - Tenofovir alafenamide en remplacement de tenofovir disoproxil fumarate chez des adultes en succes virologique
by Raffi, F and Slama, L and Yazdanpanah, Y and Cheret, A and Reynes, J and Mingjin, Y and Cheng, A and Rhee, M
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 122
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text VIH-19 - Comparaison randomisee, en double aveugle, de tenofovir alafenamide , en association avec elvitegravir, cobicistat et emtricitabine en initiation de traitement du VIH-1 : resultats a 96 semaines
by Reynes, J and Yazdanpanah, Y and Cotte, L and Molina, J.-M and Ajana, F and Girard, P.-M and Katlama, C and Wohl, D and Das, M and Fordyce, M
Médecine et maladies infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 123
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
by De Clercq, Erik
Biochemical pharmacology, ISSN 0006-2952, 11/2016, Volume 119, pp. 1 - 7
TDF (tenofovir disoproxil fumarate) | HBV (hepatitis B virus) | HIV (human immunodeficiency virus) | TAF (tenofovir alafenamide) | TFV (tenofovir) | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | HIV Infections - prevention & control | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Antiviral Agents - therapeutic use | Humans | Tenofovir - administration & dosage | Tenofovir - economics | Antiviral Agents - administration & dosage | Adenine - administration & dosage | Adenine - economics | Adenine - therapeutic use | HIV Infections - drug therapy | Antiviral Agents - economics | Tenofovir | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Tenofovir nephrotoxicity
by Isnard-Bagnis, Corinne and Aloy, Blandine and Deray, Gilbert and Tourret, JeRoMe
Néphrologie & thérapeutique, ISSN 1769-7255, 06/2016, Volume 12, Issue 3, p. 179
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate
by Margot, Nicolas A and Liu, Yang and Miller, Michael D and Callebaut, Christian
Antiviral research, ISSN 0166-3542, 08/2016, Volume 132, pp. 50 - 58
Resistance | HIV-1 | Tenofovir alafenamide | Tenofovir diphosphate | Tenofovir disoproxil fumarate | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Virology | Anti-HIV Agents - pharmacology | Cell Line | HIV-1 - drug effects | HIV Infections - virology | Humans | Tenofovir - pharmacology | Drug Resistance, Viral | Reverse Transcriptase Inhibitors - pharmacology | Tenofovir - chemistry | HIV-1 - genetics | Reverse Transcriptase Inhibitors - chemistry | Viral Load | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-HIV Agents - chemistry | Recombination, Genetic | Tenofovir - analogs & derivatives | RNA, Viral | Mutation | Tenofovir | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Plasma tenofovir levels to support adherence to TDF/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California
by Landovitz, Raphael J and Beymer, Matthew and Kofron, Ryan and Amico, Kathy Rivet and Psaros, Christina and Bushman, Lane and Anderson, Peter L and Flynn, Risa and Lee, David P and Bolan, Robert K and Jordan, Wilbert C and Tseng, Chi-Hong and Dierst-Davies, Rhodri and Rooney, Jim and Wohl, Amy Rock
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 2017, Volume 76, Issue 5, pp. 501 - 511
Adherence | HIV prevention | PrEP | MSM | Preexposure prophylaxis | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | HIV Infections - prevention & control | Tenofovir - blood | HIV Infections - epidemiology | Humans | Tenofovir - pharmacology | Los Angeles - epidemiology | Male | Tenofovir - administration & dosage | Pre-Exposure Prophylaxis | Young Adult | Transgender Persons | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Adolescent | Biomarkers | Adult | Female | Patient Compliance | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacology | Intervention | Emtricitabine | Drugs | Homosexuality | Sexually transmitted diseases--STD | Prophylaxis | Sex | Health risks | Preventive medicine | Quantitation | Patient compliance | Adhesion | Seroconversion | Prevention | Tenofovir | Prescription drugs | Men | Transgender persons | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid
by Ocque, Andrew J and Hagler, Colleen E and Morse, Gene D and Letendre, Scott L and Ma, Qing
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | Index Medicus | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
by Klatt, Nichole R and Cheu, Ryan and Birse, Kenzie and Zevin, Alexander S and Perner, Michelle and Noël-Romas, Laura and Grobler, Anneke and Westmacott, Garrett and Xie, Irene Y and Butler, Jennifer and Mansoor, Leila and McKinnon, Lyle R and Passmore, Jo-Ann S and Karim, Quarraisha Abdool and Karim, Salim S. Abdool and Burgener, Adam D
Science (American Association for the Advancement of Science), ISSN 0036-8075, 06/2017, Volume 356, Issue 6341, pp. 938 - 945
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | HIV Infections - prevention & control | Antiviral Agents - pharmacology | Bacteria - metabolism | Microbiota - physiology | Humans | Tenofovir - pharmacology | Proteome | Antiviral Agents - metabolism | Biodiversity | Lactobacillus - metabolism | Bacteria - genetics | HIV Infections - microbiology | Bacteria - isolation & purification | Microbiota - genetics | Mass Spectrometry | Tenofovir - analysis | Tenofovir - metabolism | RNA, Ribosomal, 16S - genetics | Adult | Female | South Africa | Vagina - microbiology | Gardnerella - metabolism | Anaerobic bacteria | Medical research | Correlation | Effectiveness | Communities | Mucosa | Clinical trials | Vagina | Pharmacology | Infections | Metabolism | Incidence | Prevention | Tenofovir | Depletion | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Men | Bacteria | Index Medicus | Drugs | Strategy | Human immunodeficiency virus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate
by Golla, Vijaya Madhyanapu and Kurmi, Moolchand and Shaik, Karimullah and Singh, Saranjit
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 11/2016, Volume 131, pp. 146 - 155
MSn | Tenofovir alafenamide fumarate | Prodrug | LC-HRMS | Tenofovir disoproxil fumarate | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Anti-Retroviral Agents - chemistry | Prodrugs - analysis | Drug Stability | Humans | Tenofovir - chemistry | Prodrugs - chemistry | Prodrugs - metabolism | Anti-Retroviral Agents - metabolism | Anti-HIV Agents - analysis | Anti-HIV Agents - chemistry | Anti-Retroviral Agents - analysis | Tenofovir - analysis | Tenofovir - metabolism | Anti-HIV Agents - metabolism | Tenofovir | Comparative analysis | Highly active antiretroviral therapy | Drugs | Mass spectrometry | High performance liquid chromatography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The Epi-TAF for tenofovir disoproxil fumarate?
by Walensky, Rochelle P and Horn, Tim H and Paltiel, A. David
Clinical infectious diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 7, pp. 915 - 918
cost-effectiveness | costs | tenofovir alafenamide | tenofovir disoproxil fumarate | generics | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Bone Diseases - chemically induced | Anti-HIV Agents - economics | Tenofovir - adverse effects | Tenofovir - therapeutic use | HIV Infections - economics | United States | Anti-HIV Agents - adverse effects | Humans | Tenofovir - economics | Cost-Benefit Analysis | Kidney Diseases - chemically induced | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Tenofovir | Diagnosis | Research | HIV (Viruses) | Antiretroviral drugs | Toxicity | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model
by Prathipati, Pavan Kumar and Mandal, Subhra and Pon, Gregory and Vivekanandan, Renuga and Destache, Christopher J
Pharmaceutical research, ISSN 0724-8741, 12/2017, Volume 34, Issue 12, pp. 2749 - 2755
Biochemistry, general | tissue distribution profile | nanoformulation | Biomedicine | Pharmacy | elvitegravir | pharmacokinetics | Medical Law | tenofovir alafenamide | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Tenofovir - blood | Nanoparticles - chemistry | Humans | Tenofovir - chemistry | Delayed-Action Preparations - chemistry | Tenofovir - administration & dosage | Tenofovir - pharmacokinetics | Drug Carriers - chemistry | Anti-HIV Agents - administration & dosage | Tissue Distribution | Quinolones - blood | Anti-HIV Agents - chemistry | Quinolones - administration & dosage | Animals | Quinolones - chemistry | Quinolones - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Female | HIV Infections - drug therapy | Mice | Anti-HIV Agents - blood | Tenofovir | Medical colleges | Analysis | CD34 antigen | Drugs | Stress concentration | Prophylaxis | Pharmacology | Exposure | Nanoparticles | Load distribution (forces) | Antiretroviral agents | Rodents | Sustained release | Drug dosages | Controlled release | Index Medicus | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pre-Exposure Prophylaxis for HIV Prevention : Safety Concerns
by Tetteh, Raymond A and Yankey, Barbara A and Nartey, Edmund T and Lartey, Margaret and Leufkens, Hubert G M and Dodoo, Alexander N O
Drug safety, ISSN 0114-5916, 04/2017, Volume 40, Issue 4, pp. 273 - 283
HIV Infections | Tenofovir | Animals | Humans | Anti-HIV Agents | Review | Journal Article | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Pre-Exposure Prophylaxis | Medicine & Public Health | Drug Safety and Pharmacovigilance | Pharmacology/Toxicology | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Anti-HIV Agents - administration & dosage | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Tenofovir - adverse effects | Anti-HIV Agents - adverse effects | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Tenofovir - administration & dosage | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects | Prevention | Clinical trials | Usage | Drug therapy | HIV infection | Intervention | Renal function | Toxicity | Liver | Prophylaxis | Viruses | Infections | Incidence | Mens health | Hepatitis | Acquired immune deficiency syndrome--AIDS | Vomiting | Human immunodeficiency virus--HIV | Risk assessment | Search engines | Bone density | Safety | Product safety | Drug dosages | Drug use | Monitoring | Emtricitabine | Enzymes | Medical research | Effectiveness | Health risks | Diarrhea | Exposure | Nausea | Pharmacology | Disease control | Disease prevention | Side effects | Disease transmission | Reviews | Bone mineral density | Kidney transplantation | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
by Fonner, Virginia A and Dalglish, Sarah L and Kennedy, Caitlin E and Baggaley, Rachel and O’Reilly, Kevin R and Koechlin, Florence M and Rodolph, Michelle and Hodges-Mameletzis, Ioannis and Grant, Robert M
AIDS (London), ISSN 0269-9370, 07/2016, Volume 30, Issue 12, pp. 1973 - 1983
meta-analysis | HIV prevention | HIV | preexposure prophylaxis | systematic review | tenofovir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Tenofovir - adverse effects | Administration, Oral | Anti-HIV Agents - adverse effects | Humans | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Chemoprevention - adverse effects | Young Adult | Adult | Female | Placebos - administration & dosage | Chemoprevention - methods | Index Medicus | AIDS/HIV | Epidemiology and Social
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights